Despite advances in computational chemistry and structural biology, drug design remains exceedingly difficult. Approximately 90% of proteins in the human proteome remain “undruggable” (i.e., they lack an obvious pocket for a drug to bind), and over 50% contain disordered regions that preclude detailed crystallographic analysis. As a result of these challenges, many entire classes of important proteins lack targeted therapeutics of any kind.
Many compound libraries include molecules chosen for their synthetic accessibility, drug-like attributes (Lipinski's rule of five), or historical origin. Many molecular trajectories remain unexplored simply because they’re different.
Proteins move, and their motion can reveal hidden sites that allow small molecules to control protein function from nonintuitive positions (e.g., a site distal to the active site of an enzyme). These sites, which are promising starting points for drug development, are challenging to find with existing biophysical methods.
Small-molecule drugs can function by binding to a single protein, multiple proteins, or, perhaps, a protein in a special biophysical state. Screens for molecules that achieve these multifaceted objectives are challenging to assemble.
Once discovered, promising molecules must be synthesized in quantities sufficient for biochemical analysis, optimization, formulation, and clinical evaluation. For many interesting molecules, this synthesis is time-consuming and expensive.
Think Bioscience is using synthetic biology to address these challenges. With the aid of engineered microbial systems, we are developing therapeutics against elusive targets.
Use biosynthetic machinery to explore a novel molecular search space in drug discovery.
Discover small-molecule modulators of proteins that lack crystal structures, sample multiple conformations, or contain highly disordered regions.
Design microbial systems to find bioactive compounds with improved efficacy and specificity.
Generate large quantities of promising molecules through simple fermentation.
Protein tyrosine phosphatases (PTPs) catalyze the hydrolytic dephosphorylation of tyrosine residues and contribute to a striking variety of diseases (e.g., diabetes, cancer, autoimmunity, neurological disorders, deafness, and heart disease). Despite this contribution, there are no FDA-approved therapeutics that target PTPs.
Protein tyrosine kinases (PTKs) catalyze the phosphorylation of tyrosine residues, regulating essentially all aspects of cellular function, and contributing to virtually every major therapeutic area. Although there are over 50 FDA-approved drugs that target PTKs, a substantial number of PTKs have not yet been drugged while new drug-resistant mutants continue to arise.
Transcription factors regulate the transcription of DNA into RNA. Anomalously regulated—or assembled—transcription factors contribute to autoimmune diseases and several types of cancer. Although approximately 10% of prescribed drugs target the nuclear receptor class of TFs, most promising TF targets have no approved therapeutics.
Our platform is target-agnostic. We are drawn to difficult targets, particularly those with ill-defined (e.g., disordered) structures, suboptimal (e.g., charged) binding sites, or conditional deleterious effects.